When Mikhail Blagosklonny and his team of specialists founded Oncotarget several years ago, they did not know that they were going to impact so many lives in the world. However, several years later, the journal has accomplished so much, and it is now considered to be among the most influential scientific journals in the competitive market. The scientific journal specializes in one of the most sensitive matters in the modern times, and this explains why it has gained so much popularity in the recent times. Oncotarget publishes scientific research, especially on the matters concerning cancer, a deadly medical condition that is slowly threatening the longevity of human life.
In the recent times, the number of people living with various forms of cancer has significantly gone up. Medical experts from all walks of life have been doing their best so that they can come up with the best type of treatment that will be able to bring a smile to the lives of cancer patients. Most of the cancer treatment therapies are quite expensive, and they sometimes leave the patient with serious effects, and this makes them dangerous to the cancer patients. Medical experts in the world are still conducting medical researches so that they can come up with the best forms of treatment for the patients. Oncotarget, on the other hand, has a team of reliable experts who have been doing all they can so that they can come up with the right cancer therapies. This team is led by Mikhail Blagosklonny who serves as the chief editor of the great journal.
While serving at Oncotarget as the chief editor, the scientist has done his best so that he can bring scientists together so that they can work as a team. The team has made a lot of positive impact in the oncology world, and this is why they have won the hearts of so many individuals in the competitive market. The team makes sure that the consumers from all over the world access medical knowledge at the right time. The journal has published numerous studies since its introduction into the oncology market.